PTEN-deficient cancers depend on PIK3CB
暂无分享,去创建一个
Alice T. Loo | D. Wiederschain | F. Stegmeier | C. Lengauer | S. Maira | Yung-mae M. Yao | S. Wee | Christine Miller | Rosalie deBeaumont | Rosalie S. deBeaumont
[1] K. Shokat,et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. , 2008, The Biochemical journal.
[2] M. Loda,et al. Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.
[3] Pier Paolo Pandolfi,et al. Tenets of PTEN Tumor Suppression , 2008, Cell.
[4] P. Furet,et al. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. , 2008, Bioorganic & medicinal chemistry letters.
[5] C. García-echeverría,et al. Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery , 2008, Expert opinion on therapeutic targets.
[6] D. Wiederschain,et al. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development , 2008, Current opinion in oncology.
[7] G. Mills,et al. A new mutational AKTivation in the PI3K pathway. , 2007, Cancer cell.
[8] F. Al-Dayel,et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma , 2007, Leukemia.
[9] M. Waterfield,et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. , 2007, Cancer research.
[10] Wei Wang,et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. , 2007, The Journal of clinical endocrinology and metabolism.
[11] Yunyu Zhang,et al. Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy , 2007, Proceedings of the National Academy of Sciences.
[12] T. Roberts,et al. PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target , 2006, Science's STKE.
[13] K. Okkenhaug,et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.
[14] Ximing J. Yang,et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.
[15] H. Kubo,et al. Specific role for p85/p110beta in GTP-binding-protein-mediated activation of Akt. , 2005, The Biochemical journal.
[16] Frank McCormick,et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.
[17] R. Parsons,et al. Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice , 2005, Current Biology.
[18] J. Ptak,et al. Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.
[19] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[20] Xin Huang,et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.
[21] A. Robertson,et al. PI 3-kinase p110β: a new target for antithrombotic therapy , 2005, Nature Medicine.
[22] A. Lash,et al. Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.
[23] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[24] Suk Woo Nam,et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.
[25] A. Robertson,et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. , 2005, Nature medicine.
[26] Wayne A. Phillips,et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.
[27] Hiroyuki Konishi,et al. The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.
[28] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[29] A. Lichtenstein,et al. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway , 2003, Oncogene.
[30] D. Staunton,et al. Selective role of PI3Kδ in neutrophil inflammatory responses , 2003 .
[31] D. Staunton,et al. Selective role of PI3K delta in neutrophil inflammatory responses. , 2003, Biochemical and biophysical research communications.
[32] K. Okkenhaug,et al. Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.
[33] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.
[34] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[35] P. Shepherd,et al. Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110α and p110β catalytic subunits of class-Ia phosphoinositide 3-kinases , 2000 .
[36] P. Shepherd,et al. Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases. , 2000, The Biochemical journal.
[37] H. Feilotter,et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma , 1999, British Journal of Cancer.
[38] L. Pirola,et al. Structure and function of phosphoinositide 3-kinases. , 1998, Biochimica et biophysica acta.
[39] Tomohiko Maehama,et al. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.
[40] G. Finocchiaro,et al. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas , 1998, Oncogene.
[41] J. Herman,et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.
[42] S. Hoshino,et al. Heterodimeric Phosphoinositide 3-Kinase Consisting of p85 and p110β Is Synergistically Activated by the βγ Subunits of G Proteins and Phosphotyrosyl Peptide* , 1997, The Journal of Biological Chemistry.
[43] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[44] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[45] S. Hoshino,et al. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. , 1997, The Journal of biological chemistry.